CA
TNGX icon

Clearstead Advisors’s Tango Therapeutics TNGX Stock Holding History

Clearstead Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45
Closed -$942 – 3725
2026
Q1 		$942 Hold
45
– – ﹤0.01% 2053
2025
Q4 		$399 Buy
+45
New +$388 ﹤0.01% 2334

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Clearstead Advisors's TNGX Position: Q2 2026 in Review

Clearstead Advisors sold out of Tango Therapeutics (TNGX) in Q2 2026, closing a stake of 45 shares — an estimated $942 sold.

Clearstead Advisors first reported a position in TNGX in Q4 2025 and held it in 2 quarters. The position peaked at $942 in Q1 2026. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Clearstead Advisors reported no remaining Tango Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Clearstead Advisors sold 45 Tango Therapeutics shares in Q2 2026, an estimated $942.
  • Clearstead Advisors first reported a position in Tango Therapeutics in Q4 2025 and held it in 2 quarters.
  • Clearstead Advisors's Tango Therapeutics position peaked at $942 in Q1 2026.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.